Multiplex Immunoassay Market size was valued at USD 3.3 billion in 2021 and is expected to reach USD 5.4 billion by 2028, at a CAGR of 7.1% during the forecast period 2022 to 2028. Owing introduction of newer technological advancements that have allowed for more robust multiplex assays in the detection of complex diseases and monitoring dozens of proteins at once, thereby optimizing clinical research and aiding in the discovery of new therapeutic options and multiplex assays can enable the researchers to receive more data from a sample when compared to singleplex such as ELISA or western blot and is a faster procedure and also saves both the time and cost are expected to fuel the growth of multiplex immunoassay market. Moreover, increasing research activities and rising prevalence of chronic diseases coupled with increase in number of pharmaceutical and biopharmaceutical companies are expected to propel the growth of the market. However, requirement of specialized equipment and validated antibody pair for multiplex immunoassay hampers the growth of the market over future years. The report studies global multiplex immunoassay market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global multiplex immunoassay market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities).